What is Cresemba and what is it used for?

Cresemba is an anti-fungal medicine that works by killing or stopping the growth of the fungus, which causes the infection.

Cresemba is used in patients from 1 year of age and older to treat the following fungal infections:

• invasive aspergillosis, caused by a fungus in the ‘Aspergillus’ group;
• mucormycosis, caused by a fungus belonging to the ‘Mucorales’ group in patients for whom a treatment with amphotericin B is not appropriate.

The medicine can only be obtained with a prescription.


Reference information

The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU). The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See EMA guidance on Cresemba.

If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Cresemba visit the electronic Medicines Compendium (eMC).

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.